Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 4/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20406580 | 0.93 | GPBAR1 (0.40) | DRD1GPBAR1PDE10APPP1CAKMT2A | |
| SCHEMBL18661462 | 0.92 | GPBAR1 (0.39) | DRD1GPBAR1PDE10APPP1CAKMT2A | |
| SCHEMBL20755024 | 0.91 | GPBAR1 (0.41) | DRD1GPBAR1PDE10AABL1 | |
| SCHEMBL20406584 | 0.91 | GPBAR1 (0.41) | DRD1GPBAR1PDE10AABL1 | |
| SCHEMBL20406569 | 0.91 | DRD1 (0.40) | DRD1GPBAR1PDE10APPP1CAKMT2A | |
| SCHEMBL18661464 | 0.90 | KMT2A (0.43) | DRD1PDE10APPP1CAKMT2A | |
| SCHEMBL20406168 | 0.87 | PDE10A (0.47) | DRD1GPBAR1PDE10APPP1CAKMT2A | |
| SCHEMBL20406574 | 0.86 | DRD1 (0.40) | DRD1GPBAR1PDE10A | |
| SCHEMBL20394443 | 0.86 | DRD1 (0.39) | DRD1GPBAR1PDE10APPP1CAKMT2A | |
| SCHEMBL20406233 | 0.82 | DRD1 (0.45) | DRD1PDE10APPP1CAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647675-B2 | Biaryl derivative and medicine containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-05-12 | — | — | US | disclosed |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3351533-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647675-B2 | Biaryl derivative and medicine containing same | MAN2B1, CBR3, MANBA | DRD1 1032/4885GPBAR1 2116/4885PDE10A 4605/4885 |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | MAN2B1, CBR3, MANBA | DRD1 1032/4885GPBAR1 2116/4885PDE10A 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.